AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 11420326 — intervention group
Group type: EXPERIMENTAL
Intervention: Foot length based estimates
Number of subjects: 59
Study 11420326 — intervention group
Group type: COMPARATOR
Intervention: Body weight based estimates
Number of subjects: 59
Study 9226055 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide (BUD) 400 micrograms
Number of subjects: 0
Study 9226055 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide (BUD) 800 micrograms
Number of subjects: 0
Study 9226055 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide (BUD) 100 micrograms
Number of subjects: 0
Study 9226055 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide (BUD) 200 micrograms
Number of subjects: 0
Study 9226055 — intervention group
Group type: EXPERIMENTAL
Intervention: Beclomethasone dipropionate (BDP) 800 micrograms
Number of subjects: 0
Study 9226055 — intervention group
Group type: EXPERIMENTAL
Intervention: Beclomethasone dipropionate (BDP) 100 micrograms
Number of subjects: 0
Study 9226055 — intervention group
Group type: EXPERIMENTAL
Intervention: Beclomethasone dipropionate (BDP) 200 micrograms
Number of subjects: 0
Study 9226055 — intervention group
Group type: EXPERIMENTAL
Intervention: Beclomethasone dipropionate (BDP) 400 micrograms
Number of subjects: 0
Study 8387071 — intervention group
Group type: EXPERIMENTAL
Intervention: 9 mg/kg caffeine
Number of subjects: 16
Study 8387071 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 mg/kg caffeine
Number of subjects: 16
Study 8387071 — intervention group
Group type: COMPARATOR
Intervention: Placebo (9 mg/kg dextrose)
Number of subjects: 16
Study 3680589 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular midazolam 0.050 mg/kg
Number of subjects: 10
Study 3680589 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular midazolam 0.075 mg/kg
Number of subjects: 10
Study 3680589 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular midazolam 0.100 mg/kg
Number of subjects: 10
Study 3680589 — intervention group
Group type: COMPARATOR
Intervention: Placebo (vehicle)
Number of subjects: 10
Study 3680589 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular midazolam (various doses)
Number of subjects: 10
Study 3680589 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular midazolam
Number of subjects: 10
Study 30002707 — intervention group
Group type: EXPERIMENTAL
Intervention: Median nerve neural mobilization (MNNM)
Number of subjects: 62
Study 30002707 — intervention group
Group type: COMPARATOR
Intervention: Oral ibuprofen (OI) 1200 mg/day
Number of subjects: 62
Study 30002707 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervical rotation range of motion (CROM)
Number of subjects: 62
Study 28381812 — intervention group
Group type: EXPERIMENTAL
Intervention: Theaflavin-containing fermentation water
Number of subjects: 2
Study 28381812 — intervention group
Group type: COMPARATOR
Intervention: Water without theaflavin
Number of subjects: 2
Study 26637079 — intervention group
Group type: EXPERIMENTAL
Intervention: High-alarm framing
Number of subjects: 131
Study 26637079 — intervention group
Group type: COMPARATOR
Intervention: Low-alarm framing
Number of subjects: 131
Study 23763455 — intervention group
Group type: EXPERIMENTAL
Intervention: MSC
Number of subjects: 27
Study 23763455 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study 19933744 — intervention group
Group type: EXPERIMENTAL
Intervention: Abatacept (approximately 10 mg/kg) for 6 months
Number of subjects: 50
Study 19933744 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 19933744 — intervention group
Group type: EXPERIMENTAL
Intervention: Abatacept
Number of subjects: 50
Study 19933744 — intervention group
Group type: COMPARATOR
Intervention: Abatacept and Placebo
Number of subjects: 50
Study 18949179 — intervention group
Group type: EXPERIMENTAL
Intervention: captopril 100 mg/day
Number of subjects: 15
Study 18949179 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 15
Study 18949179 — intervention group
Group type: EXPERIMENTAL
Intervention: captopril 50 mg/kg/day (in rats)
Number of subjects: 15
Study 16981922 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiofrequency ablation lesions resulting in bubble formation (327 lesions)
Number of subjects: 46
Study 16981922 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiofrequency generator power settings during lesions resulting in bubble formation
Number of subjects: 46
Study 16981922 — intervention group
Group type: EXPERIMENTAL
Intervention: Generator temperature settings during RF ablation
Number of subjects: 46
Study 16981922 — intervention group
Group type: EXPERIMENTAL
Intervention: Lesions associated with bubble formation occurring within 2-10 seconds after RF was begun
Number of subjects: 46
Study 16981922 — intervention group
Group type: EXPERIMENTAL
Intervention: Bubble formation frequency in different pulmonary veins
Number of subjects: 46
Study 12632438 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg/day of oral tiludronate for 3 months
Number of subjects: 31
Study 12632438 — intervention group
Group type: COMPARATOR
Intervention: Healthy control subjects
Number of subjects: 31
Study 11154142 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral 17beta-estradiol (2 mg daily) for 8 weeks
Number of subjects: 25
Study 11154142 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 9329065 — intervention group
Group type: EXPERIMENTAL
Intervention: 12 oz unsweetened coffee
Number of subjects: 13
Study 9329065 — intervention group
Group type: EXPERIMENTAL
Intervention: 24 oz sugar-free cola
Number of subjects: 13
Study 9329065 — intervention group
Group type: COMPARATOR
Intervention: 2 capsules
Number of subjects: 13
Study 8224679 — intervention group
Group type: COMPARATOR
Intervention: Epinephrine injection
Number of subjects: 200
Study 8224679 — intervention group
Group type: EXPERIMENTAL
Intervention: Epinephrine injection followed by 3% sodium tetradecyl sulfate
Number of subjects: 200
Study 2844333 — intervention group
Group type: EXPERIMENTAL
Intervention: Acyclovir (ACV)
Number of subjects: 42
Study 2844333 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study 29594819 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum IL-16 levels
Number of subjects: 932
Study 29594819 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum IL-16 levels among Caucasian men with a history of gonorrhea
Number of subjects: 932
Study 29594819 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum IL-16 levels among Caucasian men without a history of gonorrhea
Number of subjects: 932
Study 29594819 — intervention group
Group type: COMPARATOR
Intervention: Serum IL-16 levels among African-Americans
Number of subjects: 932
Study 28232949 — intervention group
Group type: EXPERIMENTAL
Intervention: ELKa system (n = 53)
Number of subjects: 106
Study 28232949 — intervention group
Group type: COMPARATOR
Intervention: Conventional calculation methods (n = 53)
Number of subjects: 106
Study 25278139 — intervention group
Group type: COMPARATOR
Intervention: Dexamethasone/Metoclopramide
Number of subjects: 70
Study 25278139 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium Sulfate
Number of subjects: 70
Study 23306407 — intervention group
Group type: EXPERIMENTAL
Intervention: Bubble CPAP (BCPAP)
Number of subjects: 114
Study 23306407 — intervention group
Group type: COMPARATOR
Intervention: Ventilator-derived CPAP (VCPAP)
Number of subjects: 114
Study 23306407 — intervention group
Group type: EXPERIMENTAL
Intervention: Failure of CPAP (both groups)
Number of subjects: 114
Study 21815126 — intervention group
Group type: EXPERIMENTAL
Intervention: Stretching (low-intensity exercise)
Number of subjects: 11
Study 21815126 — intervention group
Group type: COMPARATOR
Intervention: Walking (moderate-intensity exercise)
Number of subjects: 11
Study 18822172 — intervention group
Group type: EXPERIMENTAL
Intervention: Trial chemotherapy and FLC removal haemodialysis
Number of subjects: 90
Study 18822172 — intervention group
Group type: COMPARATOR
Intervention: Trial chemotherapy and standard high flux haemodialysis
Number of subjects: 90
Study 16445787 — intervention group
Group type: EXPERIMENTAL
Intervention: Levocetirizine 5 mg once daily
Number of subjects: 100
Study 16445787 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 15357564 — intervention group
Group type: EXPERIMENTAL
Intervention: SAM and S. boulardii
Number of subjects: 466
Study 15357564 — intervention group
Group type: COMPARATOR
Intervention: SAM alone
Number of subjects: 466
Study 15357564 — intervention group
Group type: EXPERIMENTAL
Intervention: AZT and S. boulardii
Number of subjects: 466
Study 15357564 — intervention group
Group type: COMPARATOR
Intervention: AZT alone
Number of subjects: 466
Study 12241628 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% colchicine cream applied twice daily for 10 days
Number of subjects: 16
Study 12241628 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% colchicine cream applied twice daily for 10 days
Number of subjects: 16
Study 9277046 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron supplementation (66 mg ferrous iron daily from second trimester until delivery)
Number of subjects: 118
Study 9277046 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 118
Study 8341890 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25 mg triazolam
Number of subjects: 12
Study 8341890 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg diphenhydramine
Number of subjects: 12
Study 8341890 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.6 g/kg ethanol
Number of subjects: 12
Study 8341890 — intervention group
Group type: COMPARATOR
Intervention: Ethanol placebo
Number of subjects: 12
Study 8341890 — intervention group
Group type: COMPARATOR
Intervention: Placebo pill
Number of subjects: 12
Study 3566241 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 g of intramuscular ceftriaxone
Number of subjects: 50
Study 3566241 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 g of intramuscular ceftriaxone
Number of subjects: 50
Study 3566241 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25 g of intramuscular ceftriaxone
Number of subjects: 50
Study 3566241 — intervention group
Group type: EXPERIMENTAL
Intervention: 250 mg of intramuscular ceftriaxone
Number of subjects: 50
Study 31724489 — intervention group
Group type: EXPERIMENTAL
Intervention: Isolated hypothyroxinemia
Number of subjects: 1080
Study 31724489 — intervention group
Group type: EXPERIMENTAL
Intervention: Subclinical hypothyroidism
Number of subjects: 1080
Study 31724489 — intervention group
Group type: COMPARATOR
Intervention: Pregnant women over 30 years old
Number of subjects: 1080
Study 31724489 — intervention group
Group type: COMPARATOR
Intervention: Second and third trimesters
Number of subjects: 1080
Study 31724489 — intervention group
Group type: COMPARATOR
Intervention: History of multiparity
Number of subjects: 1080
Study 31724489 — intervention group
Group type: COMPARATOR
Intervention: Residing in rural areas
Number of subjects: 1080
Study 31724489 — intervention group
Group type: COMPARATOR
Intervention: Residing in the capital province
Number of subjects: 1080
Study 31724489 — intervention group
Group type: COMPARATOR
Intervention: Thyroid peroxidase positive pregnant women
Number of subjects: 1080
Study 31724489 — intervention group
Group type: COMPARATOR
Intervention: Urinary iodine concentration (UIC)
Number of subjects: 1080
Study 27704628 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-week progressive resistance training (PRT) during radiotherapy
Number of subjects: 146
Study 27704628 — intervention group
Group type: COMPARATOR
Intervention: Control group (no exercise intervention)
Number of subjects: 146
Study 25903742 — intervention group
Group type: EXPERIMENTAL
Intervention: Nefopam (160 mg in 200 ml at a rate of 4 ml/h)
Number of subjects: 98
Study 25903742 — intervention group
Group type: EXPERIMENTAL
Intervention: Nefopam
Number of subjects: 98
Study 25903742 — intervention group
Group type: COMPARATOR
Intervention: Control (normal saline)
Number of subjects: 98
Study 23868708 — intervention group
Group type: EXPERIMENTAL
Intervention: School-based intervention program (n=94)
Number of subjects: 179
Study 23868708 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=85)
Number of subjects: 179
Study 21357827 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual therapy (telmisartan and ramipril)
Number of subjects: 0
Study 21357827 — intervention group
Group type: COMPARATOR
Intervention: Angiotensin receptor blocker (telmisartan)
Number of subjects: 0
Study 20037682 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled fluticasone
Number of subjects: 286
Study 20037682 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 286
Study 17944340 — intervention group
Group type: EXPERIMENTAL
Intervention: Titanium post
Number of subjects: 91
Study 17944340 — intervention group
Group type: COMPARATOR
Intervention: Glass fiber post
Number of subjects: 91
Study 14982495 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormone Replacement Therapy (HRT)
Number of subjects: 0
Study 14982495 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient involvement in trial design
Number of subjects: 0
Study 11237275 — intervention group
Group type: EXPERIMENTAL
Intervention: Stimulation Group (SG)
Number of subjects: 42
Study 11237275 — intervention group
Group type: COMPARATOR
Intervention: Control Group (CG)
Number of subjects: 42
Study 9509952 — intervention group
Group type: EXPERIMENTAL
Intervention: C-reactive protein (CRP) measurement
Number of subjects: 51
Study 9509952 — intervention group
Group type: COMPARATOR
Intervention: Body temperature (BT), erythrocyte sedimentation rate (ESR), and serum leukocyte concentration (L)
Number of subjects: 51
Study 7995154 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon alfa-n3 (500,000 IU, 0.1 ml) injected into each quadrant of the anal canal after surgical excision and fulguration
Number of subjects: 43
Study 7995154 — intervention group
Group type: COMPARATOR
Intervention: Saline (0.1 ml) injected into each quadrant of the anal canal after surgical excision and fulguration
Number of subjects: 43
Study 3050686 — intervention group
Group type: EXPERIMENTAL
Intervention: ALO 2145 (1.0% para‐amino‐clonidine)
Number of subjects: 165
Study 3050686 — intervention group
Group type: COMPARATOR
Intervention: Placebo (vehicle)
Number of subjects: 165
Study 31571351 — intervention group
Group type: EXPERIMENTAL
Intervention: Low FODMAP diet with dietitian guidance
Number of subjects: 80
Study 31571351 — intervention group
Group type: COMPARATOR
Intervention: Low FODMAP diet without dietitian guidance
Number of subjects: 80
Study 31571351 — intervention group
Group type: EXPERIMENTAL
Intervention: Low FODMAP diet
Number of subjects: 80
Study 31623349 — intervention group
Group type: EXPERIMENTAL
Intervention: RC supplementation (20 mg/kg/day)
Number of subjects: 14
Study 31623349 — intervention group
Group type: COMPARATOR
Intervention: PLA (placebo)
Number of subjects: 14
Study 31623349 — intervention group
Group type: EXPERIMENTAL
Intervention: Endurance training (both groups)
Number of subjects: 14
Study 28838395 — intervention group
Group type: EXPERIMENTAL
Intervention: Carboplatin plus irinotecan (CI)
Number of subjects: 71
Study 28838395 — intervention group
Group type: EXPERIMENTAL
Intervention: Carboplatin plus amrubicin (CA)
Number of subjects: 71
Study 26165918 — intervention group
Group type: EXPERIMENTAL
Intervention: Tdap-IPV (low-dose diphtheria, tetanus, acellular pertussis and inactivated polio vaccine)
Number of subjects: 0
Study 26165918 — intervention group
Group type: EXPERIMENTAL
Intervention: Tdap + OPV (low-dose diphtheria, tetanus, acellular pertussis vaccine with oral polio vaccine)
Number of subjects: 0
Study 26165918 — intervention group
Group type: EXPERIMENTAL
Intervention: DTap-IPV (standard-dose diphtheria, tetanus, acellular pertussis and inactivated polio vaccine)
Number of subjects: 0
Study 26165918 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (Tdap-IPV, Tdap + OPV, DTap-IPV)
Number of subjects: 0
Study 26165918 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 0
Study 26165918 — intervention group
Group type: EXPERIMENTAL
Intervention: Tdap + OPV
Number of subjects: 0
Study 26165918 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose diphtheria vaccines
Number of subjects: 0
Study 23230900 — intervention group
Group type: EXPERIMENTAL
Intervention: Static stretching
Number of subjects: 49
Study 23230900 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic stretching
Number of subjects: 49
Study 23230900 — intervention group
Group type: COMPARATOR
Intervention: Non-stretching (control condition)
Number of subjects: 49
Study 21709065 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor with low-dose maintenance aspirin
Number of subjects: 0
Study 21709065 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel with low-dose maintenance aspirin
Number of subjects: 0
Study 21709065 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor
Number of subjects: 0
Study 21709065 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel
Number of subjects: 0
Study 18413218 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetic subjects (n=983)
Number of subjects: 983
Study 18413218 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetic women (n=438)
Number of subjects: 983
Study 18413218 — intervention group
Group type: COMPARATOR
Intervention: Diabetic subjects in the DCCT intensive treatment group (n=479)
Number of subjects: 983
Study 17243593 — intervention group
Group type: EXPERIMENTAL
Intervention: Adper Prompt L-Pop (AP)
Number of subjects: 84
Study 17243593 — intervention group
Group type: EXPERIMENTAL
Intervention: Clearfil S3 Bond (S3)
Number of subjects: 84
Study 17243593 — intervention group
Group type: EXPERIMENTAL
Intervention: G-Bond (GB)
Number of subjects: 84
Study 17243593 — intervention group
Group type: EXPERIMENTAL
Intervention: iBond (iB)
Number of subjects: 84
Study 17243593 — intervention group
Group type: EXPERIMENTAL
Intervention: Xeno IV (XE)
Number of subjects: 84
Study 17243593 — intervention group
Group type: COMPARATOR
Intervention: Adper Single Bond Plus (SB)
Number of subjects: 84
Study 17243593 — intervention group
Group type: COMPARATOR
Intervention: Clearfil SE Bond (SE)
Number of subjects: 84
Study 14694028 — intervention group
Group type: EXPERIMENTAL
Intervention: Down syndrome (DS) group
Number of subjects: 17
Study 14694028 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate Alzheimer's disease (AD) group
Number of subjects: 17
Study 14694028 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 17
Study 10963840 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel
Number of subjects: 0
Study 10963840 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Number of subjects: 0
Study 10963840 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Number of subjects: 0
Study 10963840 — intervention group
Group type: EXPERIMENTAL
Intervention: Vinorelbine
Number of subjects: 0
Study 10963840 — intervention group
Group type: EXPERIMENTAL
Intervention: Irinotecan
Number of subjects: 0
Study 10963840 — intervention group
Group type: COMPARATOR
Intervention: Best supportive care (BSC)
Number of subjects: 0
Study 9100165 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-molecular-weight dermatan sulphate (Desmin) administered at doses of 400 mg (intravenous bolus) followed by 1200 mg/day infused intravenously for 10 days
Number of subjects: 10
Study 8227937 — intervention group
Group type: EXPERIMENTAL
Intervention: Spray to eyes that were closed
Number of subjects: 38
Study 8227937 — intervention group
Group type: COMPARATOR
Intervention: Eyedrops to eyes that were open
Number of subjects: 38
Study 8227937 — intervention group
Group type: COMPARATOR
Intervention: Eyedrops to eyes that were closed
Number of subjects: 38
Study 8227937 — intervention group
Group type: COMPARATOR
Intervention: Spray to eyes that were open
Number of subjects: 38
Study 6141187 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorpromazine
Number of subjects: 0
Study 6141187 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31409981 — intervention group
Group type: EXPERIMENTAL
Intervention: PCV-VG
Number of subjects: 76
Study 31409981 — intervention group
Group type: COMPARATOR
Intervention: VCV
Number of subjects: 76
Study 29205080 — intervention group
Group type: EXPERIMENTAL
Intervention: Respiratory Gating (RG) for left-sided patients
Number of subjects: 1327
Study 29205080 — intervention group
Group type: COMPARATOR
Intervention: Free-Breathing (FB) for left-sided patients
Number of subjects: 1327
Study 29205080 — intervention group
Group type: COMPARATOR
Intervention: Free-Breathing (FB) for right-sided patients
Number of subjects: 1327
Study 29205080 — intervention group
Group type: EXPERIMENTAL
Intervention: Normofractionated therapy
Number of subjects: 1327
Study 29205080 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypofractionated therapy
Number of subjects: 1327
Study 26936782 — intervention group
Group type: EXPERIMENTAL
Intervention: Ischemic preconditioning (IP)
Number of subjects: 14
Study 25157929 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (Total Sanitation Campaign)
Number of subjects: 5209
Study 25157929 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 5209
Study 20828304 — intervention group
Group type: EXPERIMENTAL
Intervention: Abacavir-lamivudine
Number of subjects: 385
Study 20828304 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenofovir-emtricitabine
Number of subjects: 385
Study 15576836 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.8 g of phosphatidylinositol (PI) with food
Number of subjects: 16
Study 15576836 — intervention group
Group type: EXPERIMENTAL
Intervention: 5.6 g of phosphatidylinositol (PI) with food
Number of subjects: 16
Study 15576836 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.8 g and 5.6 g of phosphatidylinositol (PI)
Number of subjects: 16
Study 11683666 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural blockade with bupivacaine
Number of subjects: 14
Study 11683666 — intervention group
Group type: COMPARATOR
Intervention: General anaesthesia with isoflurane (control group)
Number of subjects: 14
Study 9538962 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent very‐low‐calorie diet (VLCD) for 5 consecutive days during week 2, followed by intermittent VLCD therapy for 1 day/week for 15 weeks (1‐day) or for 5 consecutive days every 5 weeks (5‐day)
Number of subjects: 54
Study 9538962 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent VLCD therapy for 5 consecutive days every 5 weeks (5‐day)
Number of subjects: 54
Study 9538962 — intervention group
Group type: COMPARATOR
Intervention: Standard behavioral therapy (SBT) group with a 1,500‐1,800 kcal/day diet throughout
Number of subjects: 54